Patent Issued In U.S. For EntreMed's 2ME2 In Rheumatoid Diseases
May 3, 2013 | finanznachrichten.de
ROCKVILLE, Md., May 3, 2013 /PRNewswire/ --EntreMed, Inc. (Nasdaq: ENMD), a clinical-stage pharmaceutical company developing therapeutics for the treatment of a variety of cancers, announced the issuance of a U.S. patent...
Read more...
2ME2 EntreMed ENMD-2076 rheumatoid patent Phase kinase cancer disease